Tuesday’s Highlights at Noon: Microvision (MVIS), Novavax (NVAX), Second Sight Medical Products (EYES), EKSO BIONICS (EKSO), The ExOne Company (XONE)

So far Tuesday, April 27, NASDAQ is down -0.21% and the S&P is down -0.54%. Here are this morning’s most active stocks: Microvision (MVISResearch Report), Novavax (NVAXResearch Report), Second Sight Medical Products (EYESResearch Report), EKSO BIONICS (EKSOResearch Report) and The ExOne Company (XONEResearch Report).

Microvision is down -28.05% in midday trading to $19.88. Shares opened today at $27.63. The company has a 52-week low of $0.24 and a 52-week high of $24.18.

Novavax is up 7.33% in midday trading to $238.14. Shares opened today at $221.87. The company has a 52-week low of $16.41 and a 52-week high of $331.68. On the Street’s front, the average 12-month analyst price target for the stock is $323.00, marking a 45.58% potential upside from current levels. In a report released yesterday, B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on NVAX, with a price target of $365.00, which implies an upside of 65% from current levels. Separately, on February 24, Ladenburg Thalmann’s Michael Higgins assigned a Hold rating to the stock . Over the last 3 months, the insider sentiment on Novavax has been negative based on 36 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Second Sight Medical Products is down -6.81% in midday trading to $7.21. Shares opened today at $7.74. The company has a 52-week low of $0.69 and a 52-week high of $20.00.

See today’s analyst top recommended stocks >>

EKSO BIONICS is down -6.22% in midday trading to $5.58. Shares opened today at $5.95. The company has a 52-week low of $2.80 and a 52-week high of $14.98. On the Street’s front, the average 12-month analyst price target for the stock is $11.00, marking a 84.87% potential upside from current levels. In a report issued on February 26, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EKSO, with a price target of $11.00, which represents a potential upside of 85% from where the stock is currently trading.

The ExOne Company is down -5.43% in midday trading to $24.40. Shares opened today at $25.80. The company has a 52-week low of $6.64 and a 52-week high of $66.48. On the Street’s front, the average 12-month analyst price target for the stock is $44.25, marking a 71.51% potential upside from current levels. In a report issued on March 16, Oppenheimer analyst Martin Yang reiterated a Hold rating on XONE. Separately, on March 14, Canaccord Genuity’s Jonathan Dorsheimer maintained a Buy rating on the stock and has a price target of $46.00.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.